Synthetic DNA And The Future Of Genetic Medicine

Plasmid DNA has been the accepted starting point for genetic medicines for decades, even though regulators never loved it and the supplier base keeps shrinking.

In this conversation, host Angela interviews Kate Broderick of Artis BioSolutions, a life science executive with more than 25 years of experience in nucleic acid medicine, DNA and RNA-based vaccine development, and drug delivery innovation. Broderick draws on her history of regulatory discussions to explain how regulators view the shift, where manufacturing timelines break down, and what personalised cancer vaccines and outbreak response reveal about the cost of waiting. She also takes on the risk aversion that keeps teams with familiar processes.

Watch to hear her case for questioning the status quo.